Wave Life Sciences Q2 2026: $490.6M Cash, Insider Trading Plans, and Pipeline Progress
WVE is trading near its 52-week low of $5.02 (7.2% above the low).
Summary
Wave Life Sciences posted a $69.4M Q2 net loss with $490.6M in cash. Four top executives adopted 10b5-1 plans to sell up to 3.4M shares. Pipeline catalysts loom in H2 2026.
Key Events · Earnings and Guidance · WVE
-
Q2 2026 Financials
Net loss of $69.4M on $2.3M revenue. Cash and marketable securities of $490.6M provide runway for at least 12 months.
-
Insider Trading Plans Adopted
CEO, CSO, CFO, and CTO adopted 10b5-1 plans in May 2026 to sell up to 3,433,306 shares in aggregate through early 2027.
-
Pipeline Progress
WVE-007 Phase 2a dosing underway; WVE-006 FDA meeting on accelerated approval path scheduled for end of summer 2026; WVE-008 CTA filing expected in H2 2026.
-
Redomiciliation Update
Singapore court approved scheme of arrangement on July 14, 2026; redomiciliation to Delaware expected to take effect in August 2026.
Analysis · WVE · Life Sciences
A $69.4M net loss for Q2 2026 was reported, yet the quarter ended with $490.6M in cash and marketable securities — enough to fund operations for at least 12 months. The filing also disclosed that four top executives, including the CEO, adopted Rule 10b5-1 trading plans in May 2026 to sell up to 3.4 million shares combined. While pre-planned sales are routine, the concentration of plans among C-suite officers is notable. On the pipeline front, updates were provided on the obesity, AATD, and PNPLA3 programs, with key data readouts and regulatory meetings expected in the second half of 2026. The redomiciliation to Delaware is on track for August 2026 following Singapore court approval.
At the time of this filing, WVE was trading at $5.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.02 to $21.73. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.